Four of the leading lights in the US generics industry – Amneal, Aurobindo, Mylan and Teva – have seen their educational burden on antiretrovirals lessened after the US Food and Drug Administration eliminated the risk evaluation and mitigation strategy for Gilead’s Truvada emtricitabine/tenofovir disoproxil fumarate and its four approved generics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?